FrancophonIA/ELRC3.0 huggingface dataset:
English: Caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
Slovenian: - Zdravilo Caelyx lahko uporabljate kot sistemsko kemoterapijo prve izbire ali kot kemoterapijo druge izbire pri bolnikih, ki imajo z aidsom povezan Kaposijev sarkom in bolezen, ki je napredovala kljub predhodni kombinirani sistemski kemoterapiji z vsaj dvema od naslednjih citostatikov: alkaloid vinke, bleomicin in standardni doksorubicin (ali kakšen drug antraciklin) ter pri tistih bolnikih, ki so slabo prenašali takšno predhodno kombinirano sistemsko kemoterapijo.
English: Decrease dose by 25%; return to 4 week interval or withdraw patient per physician's assessment
Slovenian: Zmanjšajte odmerek za 25%; vrnite se na 4-tedenski razmik ali prenehajte s to terapijopo presoji zdravnika
English: At cumulative doses greater than 450 mg/m2 there were no cardiac events with Caelyx.
Slovenian: Pri kumulativnih odmerkih, večjih od 450 mg/m2, ni bilo pri zdravilu Caelyx nobenih kardialnih sopojavov.
English: The plasma pharmacokinetics of Caelyx in humans differ significantly from those reported in the literature for standard doxorubicin hydrochloride preparations.
Slovenian: Farmakokinetika zdravila Caelyx v plazmi pri ljudeh se bistveno razlikuje od farmakokinetike, opisane v literaturi za standardne pripravke doksorubicinijevega klorida.
English: Infusion-associated reactions
Slovenian: Infuzijske reakcije
English: Respiratory undesirable effects commonly occurred in clinical studies of Caelyx and may be related to opportunistic infections (OI's) in the AIDS population.
Slovenian: Neželeni učinki na dihala so bili v kliničnih študijah z zdravilom Caelyx pogosti in bi lahko bili povezani z oportunističnimi okužbami pri bolnikih z aidsom.
English: Vascular disorders uncommon venous thromboembolism, including thrombophlebitis, venous thrombosis and pulmonary embolism
Slovenian: Žilne bolezni občasni venski trombembolizem, vključno s tromboflebitisom, vensko trombozo in pljučno embolijo
English: Based on the review of the safety data of pegylated liposomal doxorubicin hydrochloride (Caelyx), a signal of lichenoid keratosis was detected with a total of 10 cases reported.
Slovenian: Na podlagi pregleda podatkov o varnosti doksorubicinijevega klorida v pegiliranem liposomskem pripravku (zdravilo Cealyx), so pri 10 poročanih primerih ugotovili varnostni signal za lihenoidno keratozo.
English: Breast cancer/Ovarian cancer Caelyx is administered intravenously at a dose of 50 mg/m once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.
Slovenian: Zdravilo Caelyx se daje intravensko v odmerku 50 mg/m2 enkrat na vsake 4 tedne, dokler bolezen ne napreduje in bolnica dobro prenaša zdravljenje.
English: A phase III randomised study of Caelyx versus doxorubicin in patients with metastatic breast cancer was completed in 509 patients.
Slovenian: Randomizirano raziskavo faze III, v kateri so zdravilo Caelyx primerjali s standardnim doksorubicinom pri bolnikih z metastatskim rakom dojk, je zaključilo 509 bolnikov.
English: The use of any diluent other than 5% (50 mg/ml) glucose solution for infusion, or the presence of any bacteriostatic agent such as benzyl alcohol may cause precipitation of Caelyx.
Slovenian: Uporaba katerega koli drugega vehikla kot 5% (50 mg/ml) raztopine glukoze za infundiranje oz. prisotnost kakršnegakoli bakteriostatika, npr. benzil alkohola, lahko povzroči obarjanje zdravila Caelyx.
English: Do not dose this cycle if before day 4; if after day 4 reduce next dose by 25% in the following cycles if bortezomib is reduced for haematologic toxicity.
Slovenian: V tem krogu ne infundirajte zdravila, če se to pojavi pred 4. dnevom, po 4. dnevu pa bolniku zmanjšajte naslednji odmerek za 25% v naslednjih krogih, če je bil odmerek bortezomiba zmanjšan zaradi hematološke toksičnosti.
English: There was a significant improvement in the primary endpoint of time to progression (TTP) for patients treated with combination therapy of Caelyx plus bortezomib compared to patients treated with bortezomib monotherapy as indicated by a risk reduction (RR) of 35% (95% CI: 21-47%), p < 0.0001, based on 407 TTP events.
Slovenian: Opazno je bilo bistveno izboljšanje kar zadeva primarni končni rezultat, ki je bil čas do napredovanja bolezni (TTP) pri bolnikih, ki so bili zdravljeni s kombinirano terapijo z zdravilom Caelyx in bortezomibom, v primerjavi s tistimi, ki so prejemali bortezomib v monoterapiji; to so ugotovili na podlagi zmanjšanja tveganja (RR) za 35% (95% interval zaupanja IZ; od 21 do 47%), p < 0,0001 na osnovi 407 TTP dogodkov.
English: Maximum plasma concentration* (µg/ml) Plasma clearance (l/h/m Volume of distribution (l/m AUC (µg/mlh)
Slovenian: Največja koncentracija v plazmi* (μg/ml) Plazemski očistek (l/h/m Volumen porazdelitve (l/m AUC (μg/ml∙h) λ1 razpolovni čas (h) λ2 razpolovni čas (h)
English: Caelyx is also used in combination with another medicine, bortezomib, to treat multiple myeloma, a cancer of the blood in patients who have received at least 1 prior therapy.
Slovenian: Zdravilo Caelyx uporabljamo tudi v kombinaciji z drugim zdravilom, bortezomibom, za zdravljenje diseminiranega plazmocitoma, vrste krvnega raka pri bolnikih, ki so že prejeli najmanj 1 vrsto predhodnega zdravljenja.
English: Caelyx contains soya oil and sodium
Slovenian: Zdravilo Caelyx vsebuje sojino olje in natrij
English: In studies performed after the repeated administration of Caelyx to rats and dogs, serious dermal inflammations and ulcer formations were observed at clinically relevant dosages.
Slovenian: V raziskavah večkratnega dajanja zdravila Caelyx podganam in psom so pri klinično relevantnih odmerkih opažali resna kožna vnetja in nastajanje razjed.
English: - Partially used vials must be discarded.
Slovenian: - Delno porabljene viale morate zavreči.
English: The most frequently reported (medicine-related treatment-emergent) adverse events in combination therapy (Caelyx + bortezomib) were nausea (40%), diarrhoea (35%), neutropaenia (33%), thrombocytopaenia (29%), vomiting (28%), fatigue (27%), and constipation (22%).
Slovenian: Najpogosteje poročani neželeni učinki (ki so bili povezani s prejemanjem zdravil in so se pojavili med zdravljenjem z njimi) pri zdravljenju z zdravilom Caelyx v kombinaciji z bortezomibom so bili slabost (40%), driska (35%), nevtropenija (33%), trombocitopenija (29%), bruhanje (28%), utrujenost (27%) in zaprtje (22%).
English: Mucositis (23% vs. 13%; grade 3/4 4% vs. 2%), and stomatitis (22% vs. 15%; grade 3/4 5% vs. 2%) were reported more commonly with Caelyx than with doxorubicin.
Slovenian: O mukozitisu (23% in 13%, 3. do 4. stopnja 4% in 2%) in stomatitisu (22% in 15%, 3. do 4. stopnja 5% in 2%) so poročali pogosteje pri zdravilu Caelyx kot pri standardnem doksorubicinu.
English: Persistent severe myelosuppression, may result in superinfection or haemorrhage.
Slovenian: Dolgotrajna huda mielosupresija lahko vodi do sekundarnih okužb ali krvavitev.
English: The haematological toxicity for ovarian cancer patients is less severe than in the AIDS-KS setting (see section for ovarian cancer patients above).
Slovenian: Hematološki toksični učinki pri bolnicah z rakom jajčnikov so manj resni kot pri bolnikih, ki imajo z aidsom povezan Kaposijev sarkom (glejte poglavje o bolnicah z rakom jajčnikov).
English: Stomatitis was reported more frequently in the combination therapy group (16%) than in the monotherapy group (3%), and most cases were grade 2 or less in severity.
Slovenian: O stomatitisu so poročali pogosteje v skupini, ki je prejemala kombinirano zdravljenje (16%) kot v skupini, ki je prejamala monoterapijo (3%), in večina primerov je bila po jakosti 2. stopnje ali manj.
English: The dose is repeated as long as you respond satisfactorily and tolerate treatment.
Slovenian: Infuzije bodo ponavljali tako dolgo, dokler se boste zadovoljivo odzivali na zdravljenje in ga boste dobro prenašali.
English: Guidelines for Caelyx dose modification
Slovenian: Smernice za prilagajanje odmerka zdravila Caelyx
English: Animal studies indicate that administration of doxorubicin hydrochloride as a liposomal formulation reduces the potential for extravasation injury.
Slovenian: Raziskave pri živalih kažejo, da uporaba liposomskega pripravka doksorubicinijevega klorida zmanjša nevarnost ekstravazacijske poškodbe.
English: Because of the potential for bone marrow suppression, periodic blood counts must be performed frequently during the course of Caelyx therapy, and at a minimum, prior to each dose of Caelyx.
Slovenian: Zaradi nevarnosti mielosupresije morate med zdravljenjem z zdravilom Caelyx pogosto in redno opravljati preiskave krvne slike, vsaj pred vsakim odmerkom zdravila.
English: The pharmacokinetic parameters of Caelyx (primarily representing pegylated liposomal doxorubicin hydrochloride and low levels of unencapsulated doxorubicin hydrochloride) observed after the 20 mg/m2 doses are presented in
Slovenian: Farmakokinetični parametri zdravila Caelyx (v prvi vrsti za pegiliran liposomski doksorubicinijev klorid in majhno koncentracijo neinkapsuliranega doksorubicinijevega klorida), ugotovljeni po odmerku 20 mg/m2, so prikazani v
English: Taking into account the PRAC Assessment Report on the PSUR(s) for doxorubicin, the scientific conclusions of the CHMP are as follows:
Slovenian: Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za doksorubicin, je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
English: Dermal toxicity
Slovenian: Dermalna toksičnost
English: AIDS-related KS program Clinical studies on AIDS-KS patients treated at 20 mg/m2 with Caelyx show that myelosuppression was the most frequent undesirable effect considered related to Caelyx occurring very commonly (in approximately one-half of the patients).
Slovenian: Raziskave pri bolnikih, ki imajo z aidsom povezan Kaposijev sarkom Klinične študije pri teh bolnikih z zdravilom Caelyx v odmerku 20 mg/m2 kažejo, da je najpogostnejši neželeni učinek, povezan z zdravilom, mielosupresija in se pojavlja zelo pogosto (pojavila se je pri približno polovici bolnikov).
English: If you are being treated for multiple myeloma, and have already received at least 1 prior therapy, Caelyx will be administered at a dose of 30 mg per square metre of your body surface area (based on your height and weight) as a 1 hour intravenous infusion on day 4 of the bortezomib 3 week regimen immediately after the bortezomib infusion.
Slovenian: Če se zdravite zaradi diseminiranega plazmocitoma in ste že prejeli najmanj 1 vrsto predhodnega zdravljenja, vam bodo zdravilo Caelyx dali v odmerku 30 mg na kvadratni meter telesne površine (ta pa je odvisna od vaše telesne višine in mase) v obliki enourne intravenske infuzije na 4. dan 3-tedenske sheme zdravljenja z bortezomibom, in sicer takoj po infuziji bortezomiba.
English: Aspartate aminotransferase increased, ejection fraction decreased, blood creatinine increased, alanine aminotransferase increased
Slovenian: Preiskave pogosti zmanjšana telesna masa zvišana vrednost aspartat aminotransferaze, zmanjšana iztisna frakcija srca, zvišana vrednost kreatinina v krvi, zvišana vrednost alanin aminotransferaze
English: Very rare cases of secondary oral cancer have been reported in patients with long-term (more than one year) exposure to Caelyx or those receiving a cumulative Caelyx dose greater than 720 mg/m2.
Slovenian: O zelo redkih primerih sekundarnega raka v ustni votlini so poročali pri bolnikih, ki so bili dalj časa (več kot eno leto) izpostavljeni zdravilu Caelyx ali pri bolnikih, ki so prejemali celokupni odmerek zdravila Caelyx, ki je bil večji od 720 mg/m2.
English: Do not administer Caelyx as a bolus injection or undiluted solution.
Slovenian: Zdravila Caelyx ne smete dati v obliki bolusne injekcije ali nerazredčene raztopine.
English: The doxorubicin hydrochloride in Caelyx is enclosed in tiny spheres called pegylated liposomes which help to deliver the medicinal product from the blood stream to the cancerous tissue rather than healthy normal tissue.
Slovenian: Doksorubicinijev klorid se v zdravilu Caelyx nahaja v obliki zelo majhnih kroglic, pegiliranih liposomov, ki pomagajo, da pride zdravilo iz krvi predvsem v rakavo tkivo, in čimmanj v zdravo normalno tkivo.
English: Redose unless patient has experienced a previous grade 3 or 4 stomatitis in which case wait an additional week
Slovenian: Ponovite odmerek, razen če ni bolnik prej imel stomatitisa 3. ali 4. stopnje; v tem primeru počakajte še en teden.
English: In contrast, 10 of 48 doxorubicin subjects who had cardiac toxicity by LVEF criteria also developed signs and symptoms of CHF.
Slovenian: Nasprotno pa so se pri 10 od 48 bolnikov, ki so prejemali standardni doksorubicin s kardiotoksičnostjo po merilih LVEF pojavili tudi znaki in simptomi kongestivnega srčnega popuščanja.
English: Caelyx is available in glass vials as a single pack or packs of ten vials.
Slovenian: Caelyx je na voljo v pakiranju z eno ali desetimi vialami.
English: Caelyx should only be administered under the supervision of a qualified oncologist specialised in the administration of cytotoxic agents.
Slovenian: Zdravilo Caelyx smete uporabljati le pod nadzorom usposobljenega onkologa, specializiranega za dajanje citotoksičnih zdravil.
English: Nausea and vomiting were reported more frequently in the combination therapy group (40% and 28%) than in the monotherapy group (32% and 15%) and were mostly grade 1 and 2 in severity.
Slovenian: O slabosti in bruhanju so poročali pogosteje v skupini za kombinirano zdravljenje (40% in 28%) kot v skupini za monoterapijo (32% in 15%), po jakosti pa sta bila večinoma 1. ali 2. stopnje.
English: The most frequently observed OI's in clinical studies were candidiasis, cytomegalovirus, herpes simplex, Pneumocystis carinii pneumonia, and mycobacterium avium complex.
Slovenian: V kliničnih študijah so bile najpogostnejše oportunistične okužbe kandidiaza, okužba s citomegalovirusom, herpes simpleks, pljučnica zaradi okužbe s Pneumocystis carinii in kompleks Mycobacterium avium.
English: Psychiatric disorders uncommon confusion
Slovenian: Psihiatrične motnje občasni zmedenost
English: Women of child-bearing potential must be advised to avoid pregnancy while they or their male partner are receiving Caelyx and in the six months following discontinuation of Caelyx therapy (see section
Slovenian: Ženskam v rodni dobi morate svetovati, naj ne zanosijo, medtem ko same ali njihov partner prejemajo zdravilo Caelyx in še šest mesecev po prenehanju zdravljenja z njim (glejte poglavje 5.3).
English: The following common adverse events were reported more often with doxorubicin than with Caelyx: nausea (53% vs. 37%; grade 3/4 5% vs. 3%), vomiting (31% vs. 19%; grade 3/4 4% vs. less than 1%), any alopecia (66% vs. 20%), pronounced alopecia (54% vs.7%), and neutropaenia (10% vs. 4%; grade 3/4 8% vs.
Slovenian: O naslednjih pogostih neželenih učinkih so poročali pogosteje pri standardnem doksorubicinu kot pri zdravilu Caelyx: navzea (53% za standardni doksorubicin in 37% za zdravilo Caelyx, za jakost 3. do 4. stopnje pa 5% in 3%), bruhanje (31% in 19%; 3. do 4. stopnja 4% in manj kot 1%), kakršna koli alopecija (66% in 20%), izrazita alopecija (54% in 7%) in nevtropenija (10% in 4%, 3. do 4. stopnja 8% in 2%).
English: A similar incidence of infusion reactions (12.4%) and treatment discontinuation (1.5%) was observed in the breast cancer program.
Slovenian: Pri bolnicah z rakom dojk so poročali o podobni incidenci infuzijskih reakcij (12,4%) in prekinitve zdravljenja (1,5%).
English: Contact your doctor immediately if: - you get reddening painful skin on your hands and feet; - you get painful reddening of the skin and/or blisters on the body or in the mouth; - you get heart problems; - you get mouth sores; - you develop a fever or any other sign of an infection; - you get sudden shortness of breath or sharp chest pain that may worsen with deep breathing or coughing; - you get swelling, warmth, or tenderness in the soft tissues of your leg, sometimes with pain which gets worse when you stand or walk.
Slovenian: Nemudoma se posvetujte z zdravnikom, če: - vam koža na dlaneh in stopalih pordi in vas boli - se pojavi boleča pordelost kože in/ali mehurji na telesu ali v ustih - se pojavijo težave s srcem - se pojavijo razjede v ustih - se vam zviša telesna temperatura ali se pojavi kakšen drug znak okužbe - se pri vas nenadno pojavijo težave z dihanjem ali ostre bolečine v prsih, ki se lahko poslabšajo z globokim dihanjem ali kašljanjem - se pojavi otekanje, občutek toplote ali občutljivost v mehkih tkivih nog včasih skupaj z bolečino, ki se poslabša, kadar stojite ali med hojo
English: Cases of secondary oral cancer have been reported in patients with long-term (more than one year) exposure to Caelyx or those receiving a cumulative Caelyx dose greater than 720 mg/m2 (see section 4.4).
Slovenian: O primerih sekundarnega raka v ustni votlini so poročali pri bolnikih, ki so bili dalj časa (več kot eno leto) izpostavljeni zdravilu Caelyx ali pri bolnikih, ki so prejemali skupni odmerek zdravila Caelyx, ki je bil večji od 720 mg/m2 (glejte poglavje 4.4).
English: In repeat dose studies conducted in animals, the toxicity profile of Caelyx appears very similar to that reported in humans who receive long-term infusions of standard doxorubicin hydrochloride.
Slovenian: V raziskavah pri živalih z večkratnimi odmerki je bil toksični profil zdravila Caelyx videti zelo podoben profilu pri ljudeh, ki so dlje časa prejemali infuzije standardnega doksorubicinijevega klorida.
English: A study has shown that Caelyx at a single intravenous dose of over twice the clinical dose produces renal toxicity in monkeys.
Slovenian: Študija je pokazala, da je zdravilo Caelyx v enkratnem intravenskem odmerku, večjem od dvakratnika kliničnega odmerka, toksično za ledvice pri opicah.
English: Do not use this medicine if you notice that it shows evidence of precipitation or any other particulate matter.
Slovenian: Tega zdravila ne uporabljajte, če opazite znake obarjanja ali če vsebuje zdravilo kakršnekoli druge vidne delce.
English: Eye disorders common retinitis
Slovenian: Očesne bolezni pogosti retinitis
English: Acute overdosing with doxorubicin hydrochloride worsens the toxic effects of mucositis, leukopaenia and thrombocytopaenia.
Slovenian: Akutno preveliko odmerjanje doksorubicinijevega klorida poslabša toksične učinke: mukozitis, levkopenijo in trombopenijo.
English: If tolerated, the infusion was completed over the next hour for a total infusion time of 90 minutes.
Slovenian: Če še vedno ni bilo težav, so infuzijo dokončali v naslednji uri, da je bil skupni čas infundiranja 90 minut.
English: In contrast to the experience in patients with breast cancer or ovarian cancer, myelosuppression appears to be the dose-limiting adverse event in patients with AIDS-KS (see section 4.8).
Slovenian: V nasprotju z izkušnjami pri bolnicah z rakom dojk ali rakom jajčnikov pa kaže, da je pri bolnikih, ki imajo z aidsom povezan Kaposijev sarkom, ravno mielosupresija tisti neželeni učinek, ki omejuje odmerek (glejte poglavje 4.8).
English: If you are being treated for breast cancer or ovarian cancer, Caelyx will be administered at a dose of 50 mg per square metre of your body surface area (based on your height and weight).
Slovenian: Če se zdravite zaradi raka dojk ali jajčnikov, boste zdravilo Caelyx prejeli v odmerku 50 mg na kvadratni meter telesne površine (izračunane na podlagi vaše telesne višine in mase).
English: Of the 418 patients treated with Caelyx 50 mg/m2/cycle, and having a baseline measurement of left ventricular ejection fraction (LVEF) and at least one follow-up measurement assessed by MUGA scan, 88 patients had a cumulative anthracycline dose of > 400 mg/m2, an exposure level associated with an increased risk of cardiovascular toxicity with conventional doxorubicin.
Slovenian: Pri 418 bolnikih, zdravljenih z zdravilom Caelyx v odmerku 50 mg/m2 na krog, pri katerih so opravili meritev vrednosti iztisnega deleža levega prekata na začetku raziskave in vsaj eno kontrolno meritev s slikanjem MUGA, jih je 88 prejelo kumulativni odmerek antraciklina > 400 mg/m2- to je količina, ki je bila pri standardnih pripravkih doksorubicina povezana z večjim tveganjem za pojav kardiovaskularne toksičnosti.
English: If you are being treated for Kaposi'sarcoma, Caelyx will be administered at a dose of 20 mg per square metre of your body surface area (based on your height and weight).
Slovenian: Če se zdravite zaradi Kaposijevega sarkoma, boste zdravilo Caelyx prejeli v odmerku 20 mg na kvadratni meter vaše telesne površine (izračunane na podlagi vaše telesne višine in mase).
English: Decreased testicular weights and hypospermia were present in rats after repeat doses 0.25mg/kg/day and diffuse degeneration of the seminiferous tubules and a marked decrease in spermatogenesis were observed in dogs after repeat doses of 1 mg/kg/day (see section 4.6).
Slovenian: Pri podganah sta se po večkratnih odmerkih  0,25 mg/kg/dan pojavili zmanjšana teža mod in hipospermija, pri psih pa so po večkratnih odmerkih 1 mg/kg/dan ugotavljali difuzno degeneracijo semenskih kanalov in izrazito zmanjšanje spermatogeneze (glejte poglavje 4.6).
English: No dosage adjustments.
Slovenian: Prilagoditev odmerka zdravila ni potrebna .
English: * for more information on bortezomib dosing and dosage adjustment, see the SPC for bortezomib
Slovenian: *za dodatne informacije o odmerjanju bortezomiba in prilagoditvi odmerka glejte povzetek glavnih značilnosti zdravila za bortezomib
English: Transient ECG changes such as T-wave flattening, S-T segment depression and benign arrhythmias are not considered mandatory indications for the suspension of Caelyx therapy.
Slovenian: Prehodne elektrokardiografske spremembe, npr. sploščenje valov T, znižanje veznice ST in benigne motnje srčnega ritma, ne zahtevajo nujno prenehanja zdravljenja z zdravilom Caelyx.
English: Partially used vials must be discarded.
Slovenian: Delno porabljene viale morate zavreči.
English: No formal medicinal product interaction studies have been performed with Caelyx, although phase II combination trials with conventional chemotherapy agents have been conducted in patients with gynaecological malignancies.
Slovenian: Formalnih raziskav medsebojnega delovanja zdravila Caelyx z drugimi zdravili ni bilo, le pri bolnicah z ginekološkimi malignomi so opravili kombinirane raziskave faze II s konvencionalnimi kemoterapevtiki.
English: Caelyx contains soya oil.
Slovenian: Zdravilo Caelyx vsebuje sojino olje.
English: Caelyx can be administered to patients with liver metastases with concurrent elevation of bilirubin and liver enzymes up to 4 x the upper limit of the normal range.
Slovenian: Zdravilo Caelyx lahko uporabite pri bolnikih z metastazami v jetrih in s sočasnim povečanjem koncentracije bilirubina in jetrnih encimov do 4-kratne zgornje meje normalnega razpona vrednosti.
English: Do not dose this cycle if before day 4; if after day 4, reduce next dose by 25%.
Slovenian: V tem krogu ne infundirajte zdravila, če se to pojavi pred 4. dnevom, po 4. dnevu pa bolniku zmanjšajte naslednji odmerek za 25%.
English: Skin and subcutaneous tissue disorders Very common
Slovenian: Bolezni kože in podkožja zelo pogosti
English: It is recommended that the Caelyx infusion line be connected through the side port of an intravenous infusion of 5% (50 mg/ml) glucose to achieve further dilution and minimise the risk of thrombosis and extravasation.
Slovenian: Priporočljivo je, da je infuzijska linija za zdravilo Caelyx prek stranskega nastavka priključena na intravensko infuzijo 5% (50 mg/ml) glukoze, da zagotovite dodatno razredčenje in na najmanjšo možno mero zmanjšate nevarnost tromboze in ekstravazacije.